Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.”
We explain more in the newest video from editors at Drug Delivery Business’s sister publication Medical Design & Outsourcing. (And for a deeper dive, check out our recent roundup of companies in the race.)
